INTERACTION. Yet another important step for the development of Life Science in the Gothenburg region was taken recently, when leading oligonucleotide experts gathered for a first physical meeting. The network conference took place on April 25-26 at GoCo Health innovation City in Mölndal.
The conference was organized by OligoNova, Sweden’s national infrastructure for oligonucleotide therapies and part of the SciLifeLab Drug Discovery and Development platform (DDD). The Director of Science for OligoNova, Pär Matsson, hopes that the research network and the national infrastructure OligoNova Hub can benefit patients by discovering findings from academic research more quickly. As a result, the process of developing drugs for groups that currently lack treatment can be simplified.
“A number of online meetings have been held during the almost one and a half years that OligoNova has been active, but this was the first physical meeting, and also the first research meeting in Sweden that focuses entirely on the development of therapeutic oligonucleotides”, says Pär Matsson.
A national ecosystem
OligoNova Network is part of the larger OligoNova project. The network aims to establish a national ecosystem for the research field therapeutic oligonucleotides, promote interactions between academia and industry, and create conditions for research and development in the field.
“It became clear at the network conference that Swedish research is internationally competitive in terms of basic biological research in the field”, says Pär Matsson.
For many of the participants, the network meeting also meant meeting with other Swedish researchers active in related specialties for the first time. The new contacts made during the meeting are expected to lead to new research collaborations – both in smaller constellations and in larger collaborative projects.
“The arena for discussions that OligoNova Network entails opens up for further exchange of research findings and experiences between experts within academica and industry. The network is a condition for a continued leading pharmaceutical and biotech industry in Sweden, and at the same time benefits academic research in the field”, says Pär Matsson.
Join OligoNova Network
Are your research activities linked to the development of therapeutic oligonucleotides? Contact firstname.lastname@example.org to register your interest and receive e-mails about upcoming activities within the OligoNova Network.
Oligonucleotide project call for OligoNova
The current national call for therapeutic oligonucleotide projects closes May 13. Read more and apply here.
SciLifeLab DDD/OligoNova continuously have discussions concerning putative therapeutic project of different modalities (small molecules, antibodies, nucleotides, new modalities). Are you interested in a consultation meeting? Please contact us via: email@example.com
BY: KATARINA TULLIA VON SYDOW